Unsafe
Majorly Non-Aligned
Patient Risk:
High
Summary
Most claims are pharmacokinetic/dosing-restart and patent-duration statements that are not supported by the provided FDA label excerpts (which only include boxed warning context and MTC-related sections). Several claims may be false or fabricated relative to the supplied label text, and key safety/administration details for these assertions cannot be verified.
Category Scores
Accurate Statements
WARNING: RISK OF THYROID C-CELL TUMORS (semaglutide/ Ozempic contains this boxed warning).
Provided label excerpts include Section 5.1 Risk of Thyroid C-Cell Tumors and related boxed-warning content.
OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2.
Section 4 Contraindications and Section 5.1 state this contraindication.
Unsupported Statements
Ozempic reaches its full effect on blood glucose after four to five weeks at a given dose.
Not supported by the provided label excerpts (only MTC-related sections were supplied).
After a dose increase, patients commonly observe changes in blood glucose readings around week four to five.
Not supported by the provided label excerpts.
Semaglutide, the active ingredient in Ozempic, has a half-life of about one week.
Not supported by the provided label excerpts.
It takes roughly five half-lives to approach steady state.
Not supported by the provided label excerpts.
Five weeks at a new dose level brings the body to the new level of exposure.
Not supported by the provided label excerpts.
Skipping a dose or restarting after a break of more than two weeks returns the drug level to zero almost completely.
Not supported by the provided label excerpts.
Restarting after a break of more than two weeks requires re-titration from the 0.25 mg start dose rather than jumping back to the previous higher dose.
Not supported by the provided label excerpts.
Restarting at a higher dose directly risks gastrointestinal side effects.
Not supported by the provided label excerpts.
The semaglutide molecule patent US 8,129,343 expires in 2026.
Not supported by the provided FDA label excerpts.
Contradictions
Important Omissions
Label-supported details (if any) regarding dosing adjustments after missed doses, time-to-steady state, half-life, and guidance for blood glucose effect timeline (e.g., the specific re-titration instructions).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Because most pharmacokinetic/titration/timeline statements and the restart-from-0.25 mg guidance are unsupported by the provided FDA label excerpts, relying on them could lead to incorrect dosing/titration assumptions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Majorly Non-Aligned
Primary Issue
Claims about pharmacokinetics (half-life, steady state), blood glucose effect timing, missed-dose/restart rules (including re-titration from 0.25 mg), and patent expiration are not supported by the provided FDA label excerpts and cannot be verified against the supplied label text.
Suggested Improvement
Limit statements to label-supported content from the supplied sections (e.g., the thyroid C-cell tumor warning/counseling and the MTC/MEN 2 contraindication) and avoid or re-check pharmacokinetic, timing, and missed-dose/restart guidance using the specific FDA label sections that contain those instructions.